Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
A combination of cagrilintide and semaglutide for weight control: the fullness hormone amylin + GLP-1 in one regimen. In the phase 3 study the pair produced about 22–23% weight loss — more than semaglutide alone.
Size: 2.4 mg + 2.4 mg
No published analyses yet.
Research, properties and limitations
AI can make mistakes
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
Research overview · reference
Below is a short summary of what the authors of published studies reported. It is not medical advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Gastrointestinal adverse events overall | Adults without diabetes with obesity, or overweight with at least one related complication; semaglutide 2.4 mg plus cagrilintide 2.4 mg subcutaneously once weekly, 68 weeks (REDEFINE 1) | 79.6% in the combination group versus 39.9% on placebo (very common on the pharmacy scale, ≥10%); mainly transient and mild-to-moderate in severity | [1] |
| Nausea | The same participants | Named among the gastrointestinal events; no separate frequency in the abstract | [1] |
| Vomiting | The same participants | Named among the gastrointestinal events; no separate frequency given | [1] |
FAQ
Find answers to questions about CagriSema and related materials.
It is a combination of two peptides — cagrilintide (a copy of the fullness hormone amylin) and semaglutide (GLP-1). They are taken together once a week and are being studied as a stronger weight-control regimen.
Source / documentationIn the phase 3 REDEFINE study, the pair reduced weight by about 22–23% on average, versus roughly 16% for semaglutide alone. The two hormone signals — amylin and GLP-1 — reinforce each other.
Source / documentationBoth peptides are injected under the skin once a week, and the doses are raised gradually — that keeps nausea down. The exact ramp-up schedules for each component are in the dosing guides on their pages.
Source / documentationThere is no finished CagriSema product on sale: the combination is not yet approved by the FDA or the EMA. But both components are sold separately — cagrilintide and semaglutide are in our catalog.
Source / documentationShare your experience
No reviews yet. Tell others what you think of this product.
CagriSema is not a single molecule but a pair of two peptides: cagrilintide and semaglutide. Cagrilintide is a copy of amylin, the fullness hormone the body releases after meals. Semaglutide works through a different hormone — GLP-1. Together they act on appetite from two sides, which is why the pair is being studied as a stronger weight-control regimen.
In the large phase 3 study (REDEFINE), the pair performed noticeably better than semaglutide alone: about 22–23% weight loss versus roughly 16%. That is why CagriSema is considered one of the strongest regimens currently in research. A detailed breakdown of the study is in our blog article on CagriSema.
Both peptides are injected under the skin once a week. Doses are raised gradually, step by step: the slow ramp-up gives the stomach time to adjust and keeps nausea down.
The most common side effects are nausea and other stomach and gut reactions. They are usually strongest while the doses are going up and ease off on a stable dose.
Status: as a standalone finished product, CagriSema is not yet approved by the FDA or the EMA, and there is no separate form on sale — which is why this page has no price. But both components can be bought separately: cagrilintide and semaglutide are in our catalog, and all peptides of this class are collected in the GLP-1 category.